pancreatic solid masses
Conditions
Interventions
enroll 
200 
patients 
with 
solid 
masses 
be 
planned 
to 
is 
Gold Standard:A. For patients undergoing surgery, the final diagnosis is the pathology of surgically removed specimens
B. The EUS-FNA result is malignant, and the final diagnosis is malignant
C. In the absence of surgical pathology and negative EUS-FNA results, at least 8 months of clinical follow-up will be performed to
Index test:It 
contrast-enhanced 
Sponsors
The Third Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 90 years old; 2. The patient is confirmed to be a solid pancreatic mass in imaging examinations (MRI, CT or ultrasound), and CH-EUS is required for auxiliary diagnosis; 3. Agree to participate in this study and sign the CH-EUS informed consent form.
Exclusion criteria
Exclusion criteria: Subjects who meet any of the following criteria cannot be selected for this trial: 1. The patients physical condition does not meet the requirements of conventional ultrasound endoscopic puncture: (1) Poor physical condition, including hemoglobin 1.5) or taking oral anticoagulants such as aspirin or warfarin within a week; (3) Anesthesia assessment failed; (4) Had acute pancreatitis within 2 weeks; (5) Pregnancy or breastfeeding; (6) Known history of allergy to sulfur hexafluoride or other components; (7) Recent acute coronary syndrome or clinically unstable ischemic heart attack; (8) Heart disease patients with right-to-left shunt, patients with severe pulmonary hypertension (pulmonary artery pressure> 90mmHg), patients with uncontrolled systemic hypertension and patients with adult respiratory distress syndrome; 2. Disagree to participate in this study; 3. There are other problems that do not meet the requirements of this research or that affect the results of the research: (1) Pancreatic disease has undergone surgery or chemotherapy beforehand; (2) The patient was diagnosed with pancreatic cystic disease or duodenal stenosis; (3) Mental illness, drug addiction, inability to express themselves or other diseases that may affect follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Accuracy;Sensitivity;Specificity;positive predictive value;negative predictive value; | — |
Secondary
| Measure | Time frame |
|---|---|
| the diagnosis rate of first needle aspiration;core tissue length; | — |
Countries
China
Contacts
Public ContactXiaoyan Wang
Department of gastroenteropathy, The Third Xiangya Hospital of Central South University
Outcome results
None listed